Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): A biomarker-stratified, randomised phase 3 trial

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages 713-721

  Gregorc, Vanesa ^a   Novello, Silvia ^b   Lazzari, Chiara ^a   Barni, Sandro ^c   Aieta, Michele ^d   Mencoboni, Manlio ^e   Grossi, Francesco ^f   Pas, Tommaso De ^g   De Marinis, Filippo ^g,h   Bearz, Alessandra ⁱ   Floriani, Irene ^j   Torri, Valter ^j   Bulotta, Alessandra ^a   Cattaneo, Angela ^a   Grigorieva, Julia ^k   Tsypin, Maxim ^k   Roder, Joanna ^k   Doglioni, Claudio ^a   Levra, Matteo Giaj ^b   Petrelli, Fausto ^c   Foti, Silvia ^a   Viganò, Mariagrazia ^a   Bachi, Angela ^a   Roder, Heinrich ^k   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e VILLA SCASSI HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h Oncological Pulmonary 1st Unit   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k Biodesix   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; PEMETREXED;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT INDICATION; TREATMENT RESPONSE;

BLOOD PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PROTEOMICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84901611575     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70162-7     Document Type: Article

References (23)

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246. on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica.
3. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR Mutations. J Clin Oncol 2013, 31:3327-3334.
4. Cardarella S, Johnson B Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts. J Natl Cancer Inst 2013, 105:589-590.
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
8. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
9. Zhu CQ, Da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
10. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012, 13:300-308.
11. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013, 14:981-988. on behalf of the TAILOR trialists.
12. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99:838-846.
13. Stinchcombe TE, Roder J, Peterman AH, et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2013, 8:443-451.
14. Vansteenkiste JF, Paz-Ares L, Eisen TQG, et al. A plasma proteomic signature predicts outcomes in a Phase 3 study of gemcitabine (G) + cisplatin (C) ± sorafenib in first line stage IIIB or IV non-small cell lung cancer (NSCLC). European Society For Medical Oncology; Vienna, Austria; Sept 28-Oct 2, 2012: 1241P (abstr).
15. Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol 2012, 7:1653-1660.
16. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010, 5:169-178.
17. Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol 2012, 7:40-48.
18. Friedlin B, McShane LM, Korn EL Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010, 102:152-160.
19. Peterson B, George SL Sample size requirements and length of study for testing interaction in a 2 × k factorial design when time-to-failure is the outcome. Control Clin Trials 1993, 14:511-522.
20. Kris M. Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: results from the Lung Cancer Mutation Consortium. 15th World Conference on Lung Cancer, Sydney, NSW, Australia; Oct 27-31, 2013. PL03 (abstr).
21. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128. for the West Japan Oncology Group.
22. Fleming TR, Rothman MD, Lu HL Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009, 17:2874-2880.
23. Milan E, Lazzari C, Anand S, et al. SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics 2012, 76:91-101.